Clinical Trial Update: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating bococizumab in subjects with hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events has completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Mixed Dyslipidemia

Drugs mentioned

• Bococizumab (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2017-05-17